HU180740B - Process for producing sulfonamide-containing,injectable pharmaceutical composition of prolongated activity - Google Patents
Process for producing sulfonamide-containing,injectable pharmaceutical composition of prolongated activity Download PDFInfo
- Publication number
- HU180740B HU180740B HU79EE2710A HUEE002710A HU180740B HU 180740 B HU180740 B HU 180740B HU 79EE2710 A HU79EE2710 A HU 79EE2710A HU EE002710 A HUEE002710 A HU EE002710A HU 180740 B HU180740 B HU 180740B
- Authority
- HU
- Hungary
- Prior art keywords
- parts
- weight
- pharmaceutical composition
- volumes
- preparation
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 17
- 238000000034 method Methods 0.000 title claims description 13
- 229940124530 sulfonamide Drugs 0.000 title description 5
- 150000003456 sulfonamides Chemical class 0.000 title description 5
- 230000000694 effects Effects 0.000 title description 2
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 claims abstract description 25
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims abstract description 20
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 8
- 239000000654 additive Substances 0.000 claims abstract description 5
- 230000000996 additive effect Effects 0.000 claims abstract description 3
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 20
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 20
- 229940093471 ethyl oleate Drugs 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 10
- 238000013268 sustained release Methods 0.000 claims description 6
- 239000012730 sustained-release form Substances 0.000 claims description 6
- 239000007972 injectable composition Substances 0.000 claims description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 2
- 125000005806 3,4,5-trimethoxybenzyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1C([H])([H])* 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- -1 methoxybenzyl Chemical group 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 7
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 5
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 229960005404 sulfamethoxazole Drugs 0.000 description 19
- 229960001082 trimethoprim Drugs 0.000 description 15
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 229940113088 dimethylacetamide Drugs 0.000 description 12
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 6
- 239000002904 solvent Substances 0.000 description 5
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 4
- 239000005977 Ethylene Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000011287 therapeutic dose Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 229940006995 sulfamethoxazole and trimethoprim Drugs 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- DJEHXEMURTVAOE-UHFFFAOYSA-M potassium bisulfite Chemical compound [K+].OS([O-])=O DJEHXEMURTVAOE-UHFFFAOYSA-M 0.000 description 1
- 235000010259 potassium hydrogen sulphite Nutrition 0.000 description 1
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 1
- 235000010263 potassium metabisulphite Nutrition 0.000 description 1
- BHZRJJOHZFYXTO-UHFFFAOYSA-L potassium sulfite Chemical compound [K+].[K+].[O-]S([O-])=O BHZRJJOHZFYXTO-UHFFFAOYSA-L 0.000 description 1
- 235000019252 potassium sulphite Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU79EE2710A HU180740B (en) | 1979-11-27 | 1979-11-27 | Process for producing sulfonamide-containing,injectable pharmaceutical composition of prolongated activity |
| FR8024891A FR2469924A1 (fr) | 1979-11-27 | 1980-11-24 | Composition pharmaceutique injectable a action prolongee, contenant comme agents actifs du sulfamethoxazole et de la trimethoprime, et son procede de preparation |
| BE1/10048A BE886310A (fr) | 1979-11-27 | 1980-11-24 | Composition pharmaceutique injectable a action prolongee et son procede de preparation |
| AT0577380A AT371339B (de) | 1979-11-27 | 1980-11-26 | Verfahren zur herstellung eines injektionspr[parates mit prolongierter wirkung |
| IT26237/80A IT1149268B (it) | 1979-11-27 | 1980-11-26 | Composizione farmaceutica iniettabile ad azione prolungata e procedimento per la sua preparazione |
| GB8037932A GB2066068B (en) | 1979-11-27 | 1980-11-26 | Injectabel composition containing sulphamethoxazole |
| JP16647880A JPS5687517A (en) | 1979-11-27 | 1980-11-26 | Medicinal composition for durable effect type injection |
| DD80225492A DD154802A5 (de) | 1979-11-27 | 1980-11-26 | Verfahren zur herstellung eines injizierbaren pharmazeutischen praeparates von prolongierter wirkung |
| DE19803044753 DE3044753A1 (de) | 1979-11-27 | 1980-11-27 | Injizierbare arzneimittelpraeparate mit verlaengerter wirkung |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU79EE2710A HU180740B (en) | 1979-11-27 | 1979-11-27 | Process for producing sulfonamide-containing,injectable pharmaceutical composition of prolongated activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HU180740B true HU180740B (en) | 1983-04-29 |
Family
ID=10995877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU79EE2710A HU180740B (en) | 1979-11-27 | 1979-11-27 | Process for producing sulfonamide-containing,injectable pharmaceutical composition of prolongated activity |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JPS5687517A (enrdf_load_stackoverflow) |
| AT (1) | AT371339B (enrdf_load_stackoverflow) |
| BE (1) | BE886310A (enrdf_load_stackoverflow) |
| DD (1) | DD154802A5 (enrdf_load_stackoverflow) |
| DE (1) | DE3044753A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2469924A1 (enrdf_load_stackoverflow) |
| GB (1) | GB2066068B (enrdf_load_stackoverflow) |
| HU (1) | HU180740B (enrdf_load_stackoverflow) |
| IT (1) | IT1149268B (enrdf_load_stackoverflow) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU210693B (en) * | 1991-10-11 | 1995-06-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing pharmaceutical compositions for injections without tissue damages, containing sulfamethoxazol and trimetoprime |
| CN100376893C (zh) * | 2006-08-18 | 2008-03-26 | 中国水产科学研究院黄海水产研究所 | 同时测定鱼肉中磺胺甲唑、乙酰化磺胺甲唑及甲氧苄啶的液相色谱法 |
| CN113952296B (zh) * | 2021-11-15 | 2023-10-13 | 山东新华制药股份有限公司 | 一种复方磺胺甲噁唑注射液的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH544053A (de) * | 1966-05-09 | 1973-11-15 | Hoffmann La Roche | Verfahren zur Herstellung von Sulfonamidderivaten |
| US3985876A (en) * | 1973-01-05 | 1976-10-12 | Burroughs Wellcome Co. | Chemotherapeutic solutions containing a sulphur and a salt of a 2,4-diamino-5-benzylpyrimidine |
| GB1469521A (en) * | 1973-01-05 | 1977-04-06 | Wellcome Found | Antimicrobial preparations |
| DK136934B (da) * | 1976-02-06 | 1977-12-19 | Rosco As | Fremgangsmåde til fremstilling af en klar, stabil, injicerbar opløsning indeholdende et sulfonamid og en potentiator. |
| DE2631779A1 (de) * | 1976-07-15 | 1978-01-19 | Basf Ag | Sulfonamid-trimethoprim-loesungen |
-
1979
- 1979-11-27 HU HU79EE2710A patent/HU180740B/hu not_active IP Right Cessation
-
1980
- 1980-11-24 BE BE1/10048A patent/BE886310A/fr not_active IP Right Cessation
- 1980-11-24 FR FR8024891A patent/FR2469924A1/fr active Granted
- 1980-11-26 IT IT26237/80A patent/IT1149268B/it active
- 1980-11-26 GB GB8037932A patent/GB2066068B/en not_active Expired
- 1980-11-26 AT AT0577380A patent/AT371339B/de not_active IP Right Cessation
- 1980-11-26 DD DD80225492A patent/DD154802A5/de not_active IP Right Cessation
- 1980-11-26 JP JP16647880A patent/JPS5687517A/ja active Granted
- 1980-11-27 DE DE19803044753 patent/DE3044753A1/de active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| IT8026227A0 (it) | 1980-11-26 |
| DD154802A5 (de) | 1982-04-21 |
| BE886310A (fr) | 1981-05-25 |
| DE3044753A1 (de) | 1981-06-19 |
| GB2066068B (en) | 1983-08-24 |
| FR2469924A1 (fr) | 1981-05-29 |
| JPS5687517A (en) | 1981-07-16 |
| DE3044753C2 (enrdf_load_stackoverflow) | 1990-05-10 |
| IT1149268B (it) | 1986-12-03 |
| GB2066068A (en) | 1981-07-08 |
| ATA577380A (de) | 1982-11-15 |
| JPH0128005B2 (enrdf_load_stackoverflow) | 1989-05-31 |
| FR2469924B1 (enrdf_load_stackoverflow) | 1984-06-29 |
| AT371339B (de) | 1983-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0546018B1 (en) | Pharmaceutical composition of florfenicol | |
| PT95451A (pt) | Processo para a preparacao de composicoes aquosas estabilizadas de pequenos peptidos | |
| KR910005885B1 (ko) | 염화리소짐 및 글리치르히진산 디칼륨 함유 수용액제제 | |
| EA035079B1 (ru) | Композиция диклофенака | |
| US5538989A (en) | Fenbendazole formulations | |
| US4259331A (en) | Oxytetracycline compositions | |
| EA013616B1 (ru) | Инъекционные препараты диклофенака и его фармацевтически приемлемых солей | |
| US20080261939A1 (en) | Stannsoporfin compositions and administration | |
| HU180740B (en) | Process for producing sulfonamide-containing,injectable pharmaceutical composition of prolongated activity | |
| JP3146218B2 (ja) | 点眼剤 | |
| JPS6011025B2 (ja) | 新規アミノ酸誘導体の製法 | |
| US3155587A (en) | Stable liquid preparations of 7-chlorotetracycline | |
| ES2232195T3 (es) | Solucion parenteral de propofol (2,6-diisopropilfenol) y 2,5-di-o-metil-1,4;3,6-dianhidro-d-glucitol como solvente. | |
| EP0236280B1 (en) | Injectable pharmaceutical formulations of active principles having general anaesthetic activity | |
| WO2021033145A1 (en) | Novel injectable formulations of artesunate | |
| EP0436015B1 (de) | Pharmazeutische zubereitung zur rektalen verabreichung | |
| HU202744B (en) | Process for producing parenteral analgetic/antipyretic | |
| JP2007045788A (ja) | グリチルリチン酸高濃度水溶液の調製法 | |
| RU2280438C2 (ru) | Средство "форидон-гель" для лечения и профилактики сердечно-сосудистых заболеваний | |
| US4742082A (en) | Solution of luprostiol and 1,2,-propanediol and methods of preparation and use | |
| RU2276983C2 (ru) | Цестодоцидная композиция для животных | |
| JPH07116039B2 (ja) | 安定な塩酸トリメトキノール内用液剤 | |
| HU210693B (en) | Process for producing pharmaceutical compositions for injections without tissue damages, containing sulfamethoxazol and trimetoprime | |
| UA63137C2 (en) | Foridon gel, drug for treatment and prevention of cardiovascular diseases | |
| JPH02500671A (ja) | 抗乾癬医薬組成物の調製方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HU90 | Patent valid on 900628 | ||
| HMM4 | Cancellation of final prot. due to non-payment of fee |